Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine in adolescents with juvenile primary fibromyalgia syndrome
NCT01089621Phase 4Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2010
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of duloxetine in Juvenile Fibromyalgia Syndrome (JFMS), sponsored by Eli Lilly and Company. Primary endpoints: Rate of enrollment at 6 months and Rate of retention at 12 weeks. Planned start Mar 2010; status: withdrawn.
02
Drugs
duloxetine
03
Conditions
Juvenile Fibromyalgia Syndrome (JFMS)
Beyond the preview
Go deeper on NCT01089621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01089621.